A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
This important study is investigating new treatments for a type of bladder cancer that has spread or can't be removed by surgery. This is called 'unresectable or metastatic urothelial cancer' and it hasn't been treated before. The trial aims to find out if a combination of two immunotherapy drugs, nivolumab and ipilimumab, or nivolumab with standard chemotherapy, works better than standard chemotherapy alone. Researchers want to see if these new treatment options help people live longer and improve their quality of life. Participants will be randomly assigned to receive one of these treatment approaches, and doctors will carefully monitor their progress. This is a Phase 3 study, meaning it's a large trial designed to confirm if new treatments are effective and safe for widespread use.
At a glance
What is this study about?
This research study is for people who have bladder cancer that has either spread to other parts of the body (metastatic) or can't be completely removed by surgery (unresectable). This is the first time these patients will be receiving treatment for this specific cancer.
The main goal of the study is to compare different treatment approaches. One approach involves a combination of two drugs called nivolumab and ipilimumab, which are types of immunotherapy. Immunotherapy works by helping your body's own immune system fight the cancer. Another approach combines nivolumab with standard chemotherapy, which are strong medicines used to kill cancer cells. The study will compare these new approaches against standard chemotherapy alone, which is the usual treatment for this condition.
Researchers want to see if the new combinations help people live longer than with standard chemotherapy. They are particularly interested in certain groups of patients: those who can't have a specific type of chemotherapy called cisplatin, and those whose cancer cells show a certain marker called PD-L1. They will also look at how these treatments affect everyone in the study and whether they improve quality of life.
Key takeaways
- This study evaluates new treatments for advanced bladder cancer.
- It compares immunotherapy combinations with standard chemotherapy.
- The main goal is to see if new treatments help people live longer.
- Participation involves receiving study medicines and regular check-ups.
- Findings could lead to better treatment options for future patients.
- You can leave the study at any time with no impact on your care.
Who may be eligible?
To be considered for this study, you must be 18 years old or older. The study is open to both men and women.
You would be eligible if you have bladder cancer that falls into the category of 'unresectable' (meaning it can't be entirely removed by surgery) or 'metastatic' (meaning it has spread to other parts of your body).
Additionally, you must not have received any prior treatment specifically for this advanced bladder cancer.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have bladder cancer that has spread or can't be removed by surgery?
- Have you not received any treatment for this advanced bladder cancer before?
- Are you able to travel to the study clinic for appointments?
What does participation involve?
If you join this study, you will be randomly assigned to one of the treatment groups: either two immunotherapy drugs, or immunotherapy plus standard chemotherapy, or standard chemotherapy alone. This is like flipping a coin, ensuring a fair comparison between the treatments. You will receive these medicines, usually through an IV drip.
Throughout the study, you will have regular visits to the clinic. These visits will involve blood tests, physical examinations, and scans (like CT or MRI) to check how the treatment is working and monitor your health. Doctors will also ask you questions about how you are feeling to understand your quality of life.
The total length of your participation will depend on various factors, including how your body responds to the treatment. You will continue to be monitored for some time after your active treatment ends.
Potential risks and benefits
Locations (11)
- —UnverifiedGermany
- —UnverifiedGreece
- —UnverifiedDenmark
- —UnverifiedFrance
- —UnverifiedRomania
- —UnverifiedPoland
- —UnverifiedNorway
- —UnverifiedCzechia
- —UnverifiedNetherlands
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is 'urothelial cancer'?
Urothelial cancer is a type of cancer that starts in the lining of the bladder, ureters, or renal pelvis. It's often called bladder cancer if it starts in the bladder.
What does 'unresectable or metastatic' mean?
Unresectable means the cancer cannot be completely removed by surgery. Metastatic means the cancer has spread from where it started to other parts of the body.
What are immunotherapy drugs like nivolumab and ipilimumab?
These are medicines that help your body's immune system recognise and fight cancer cells more effectively. They are different from traditional chemotherapy.
Why is the study 'randomized'?
Being randomized means you'll be put into a treatment group by chance, like drawing names from a hat. This is done to make sure the study results are fair and reliable.
What will happen if the new treatments work well?
If the new treatments prove to be effective and safe, they could become new standard treatment options for people with this type of bladder cancer in the future.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.